Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 2 of 3 (67%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Henlius Biotech Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners, though they are concentrated within only 2 distinct art units. This indicates that at least one art unit is hosting multiple examiners for the company's current filings.
The busiest examiner, SAOUD, CHRISTINE J, is responsible for 1 pending case. Given that there are pending office actions and distinct examiners, the workload is balanced. Managing the examiners across 2 distinct art units requires the applicant to monitor for consistency. The 1 pending case per examiner defines the current engagement.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.2% |
| SANG, HONG | 1 | 55.0% | +62.4% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17905496 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | SAOUD, CHRISTINE J | 16d overdue |
| 17822710 | ANTI-CD137 CONSTRUCTS AND USES THEREOF | SANG, HONG | 7d |
| 17822750 | ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODY AND USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905496 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | SAOUD, CHRISTINE J | 1645 | §103 | Final Rejection | 16d overdue | AI Ready | Sep 01, 2022 |
| 17822710 | ANTI-CD137 CONSTRUCTS AND USES THEREOF | SANG, HONG | 1646 | §112 | Final Rejection | 7d | AI Ready | Aug 26, 2022 |
| 17822750 | ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODY AND USES THEREOF | GUSTILO, ESTELLA M | 1646 | §112DP | Non-Final OA | — | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial